Metrics as of 10/16/2026, 08:45 AM (Berlin time), refresh in progress.
4basebio Stock
4basebio PLC
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- CEO
- Amy Jo Walker
- Employees
- 140
- Market cap
- £82 M
- IPO
- 17/02/2021
4basebio PLC, an enterprise established in 2020 and situated in Cambridge, United Kingdom, is dedicated to the entire process, from conception to delivery, of synthetic DNA and RNA products. The company also provides advanced non-viral vector solutions, with operations spanning the United States, Europe, and other…
4basebio stock: price history
1D
-5.8%
1W
-5.8%
1M
+10.4%
6M
+5.0%
YTD
-13.8%
1Y
-30.3%
2Y
-58.9%
5Y
-27.4%
10Y
–
Next earnings date
Next earnings date
02/06/2027 (in 228 days)
Volatility around earnings
~51% stronger price swings than usual
Ask the agents about 4basebio
4basebio stock metrics
P/E
-4.57
P/B
64.79
EV/EBITDA
-5.59
RETURN ON EQUITY
-702.1%
NET MARGIN
-3,406.1%
DEBT/EQUITY
18.18
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
37.1%
FLOAT SHARES
5,741,016
AVG. DAILY VOLUME (30D)
1,332
Comparable stocks
Frequently asked questions about 4basebio stock
What does 4basebio do?
4basebio PLC is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.
The CEO is Amy Jo Walker, the company employs around 140 people.
The IPO was on 17/02/2021; the stock trades on LSE under the ticker 4BB.L.
When does 4basebio report next?
The next earnings date is 02/06/2027.
Around past earnings, price swings were roughly 51% stronger than usual.
Does 4basebio pay a dividend?
No, 4basebio currently does not pay a dividend.
Which stocks are comparable to 4basebio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get 4basebio stock analyzed?
Clicking "Analyze stock" lets five strategies assess 4basebio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.